Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Regeneron Pharmaceuticals Inc. Stock

Price
Target price
€780.50

€780.50

-0.380%
-3.0
-0.380%
€861.53
 
08.12.23 / Tradegate WKN: 881535 / Symbol: REGN / Name: Regeneron / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years
Wizard

Regeneron Pharmaceuticals Inc. Stock

Regeneron Pharmaceuticals Inc. shows a slight decrease today, losing -€3.000 (-0.380%) compared to yesterday.
We see a rather positive sentiment for Regeneron Pharmaceuticals Inc. with 19 Buy predictions and 1 Sell predictions.
With a target price of 861 € there is a slightly positive potential of 10.31% for Regeneron Pharmaceuticals Inc. compared to the current price of 780.5 €.
So far the community has only identified positive things for Regeneron Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years

Pros
?
S********** s********
?
B****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Regeneron Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Regeneron Pharmaceuticals Inc. -0.380% 4.206% 1.561% 7.670% 16.025% 90.111% 137.986%
Exact Sciences -0.420% -2.418% 2.489% 38.112% 29.068% -45.455% -3.977%
Amgen Inc. -0.400% -0.239% -2.038% -7.579% 1.978% 32.219% 48.368%
Incyte Corp. -0.390% 2.336% 0.634% -36.244% -31.445% -25.702% -10.512%

Comments

Prediction Buy
Perf. (%) -0.06%
Target price 927.700
Change
Ends at 06.12.24

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at TD Cowen from $900.00 to $1,000.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Show more

TD Cowen 
0
Report Share
06.12.23
Prediction Buy
Perf. (%) 7.06%
Target price 852.483
Change
Ends at 28.11.24

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Jefferies Financial Group Inc. from $935.00 to $937.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Show more

Jefferies Financial Group Inc. 
0
Report Share
28.11.23
Prediction Buy
Perf. (%) 7.06%
Target price 951.368
Change
Ends at 28.11.24

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $1,045.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Show more

Truist Financial Co. 
0
Report Share
28.11.23
Show more
Not a member yet? Sign up for free!

News

3 biotech powerhouses poised to thrive amidst sector rebound: https://www.marketbeat.com/logos/articles/med_20231208085353_3-biotech-powerhouses-poised-to-thrive-amidst-sect.jpg
3 biotech powerhouses poised to thrive amidst sector rebound

The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant

MarketBeat 
0 08.12.23
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/756929/rich-couple-on-a-boat.jpg
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?

Regeneron Pharmaceuticals (NASDAQ: REGN) is a top pharmaceutical company with many promising assets in its portfolio. Its diverse business has enabled the business to grow over the years. In the

TheMotleyFool 
0 08.12.23
2 Soaring Stocks to Buy and Hold: https://g.foolcdn.com/editorial/images/754012/person-sitting-and-working-at-a-desk.jpg
2 Soaring Stocks to Buy and Hold

Biotech giant Regeneron (NASDAQ: REGN) and streaming specialist Roku (NASDAQ: ROKU) have been solid performers for most of the year, but both stocks recently jumped following their third-quarter

TheMotleyFool 
0 09.11.23